Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trialSéverine Vermeire, Walter Reinisch, William J. Sandborn et al.|The Lancet|2017Cited by 198
Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn’s Disease: Report of the TOSCA StudyGeert D’Haens, Olaf Stüve, Harald Vogelsang et al.|Journal of Crohn s and Colitis|2017Cited by 28
901a A Randomized, Multicenter Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in Patients With Moderate to Severe Ulcerative Colitis: Results of the TURANDOT StudyWalter Reinisch, Séverine Vermeire, William J. Sandborn et al.|Gastroenterology|2015Cited by 26
Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy BiomarkersHuanyu Zhou, Mina Hassan‐Zahraee, Xi Li et al.|Journal of Crohn s and Colitis|2019Cited by 20
OP007 Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn's disease patients who are anti-TNF inadequate responders: Results from the TOSCA studyG. D’Haens, Walter Reinisch, Séverine Vermeire et al.|Journal of Crohn s and Colitis|2014Cited by 11